Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?

Hepatocellular carcinoma (HCC) remains the sixth most commonly diagnosed malignancy worldwide, still representing an important cause of cancer-related death. Over the next few years, novel systemic treatment options have emerged. Among these, immune checkpoint inhibitors (ICIs) have been widely eval...

Descripción completa

Detalles Bibliográficos
Autores principales: Rizzo, Alessandro, Ricci, Angela Dalia, Di Federico, Alessandro, Frega, Giorgio, Palloni, Andrea, Tavolari, Simona, Brandi, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718608/
https://www.ncbi.nlm.nih.gov/pubmed/34976841
http://dx.doi.org/10.3389/fonc.2021.803133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718608/
https://www.ncbi.nlm.nih.gov/pubmed/34976841
http://dx.doi.org/10.3389/fonc.2021.803133

Ejemplares similares